Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

Clinical Trial Progress - The first patient has been dosed in the Phase 1 clinical trial for CTIM-76, marking a significant milestone in the company's clinical pipeline [1][6] - The Phase 1 trial is an open-label, dose escalation and expansion study evaluating CTIM-76 in patients with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers [4][6] - The trial aims to assess safety, tolerability, pharmacokinetics, and anti-tumor activity, with up to 70 patients expected to be enrolled [4][6] - Initial data from the CTIM-76 Phase 1 trial is anticipated to be shared in the first half of 2026 [6] CTIM-76 Overview - CTIM-76 is a Claudin 6 (CLDN6) x CD3 T cell engaging bispecific antibody targeting CLDN6-positive cancers [1][6][7] - CLDN6 is enriched in various solid tumors, including ovarian, endometrial, lung, gastric, and testicular cancers [7] - Preclinical research suggests CTIM-76 has potential for convenient dosing, low immunogenicity risk, and scalable manufacturing [7] Company Background - Context Therapeutics Inc is a biopharmaceutical company focused on developing T cell engaging (TCE) bispecific antibodies for solid tumors [2] - The company's pipeline includes CTIM-76, CT-95 (Mesothelin x CD3 bispecific antibody), and CT-202 (Nectin-4 x CD3 bispecific antibody) [2] - Context Therapeutics is headquartered in Philadelphia and is publicly traded on Nasdaq under the ticker CNTX [2]